Takeda Pharmaceutical Company Innovators in Science Award
Internal deadline: April 17, 2018
The 2019 Innovators in Science Award will recognize a promising Early-Career Scientist's and an outstanding Senior Scientist's contributions to science in the therapeutic area of Regenerative Medicine and is intended to support their commitment to innovative research.
The Early-Career Scientist nominee must:
In the event that an Early-Career Scientist nominee has taken a maternity, paternity, adoptive, family care, military, or extended sick leave (in line with their current institution's policies) during the 10 years since gaining their doctoral degree or equivalent, they can qualify for an extension of the eligibility timeframe.
The Senior Scientist nominee must:
Individuals in receipt of current or prior research support from Takeda Pharmaceutical Company Limited, or its affiliates, are not eligible for nomination.
Interested applicants should submit the following documents:
Questions? Email the Research Development Team at firstname.lastname@example.org.
Internal deadline: April 17, 2018
The mission of the Foundation is to make grants to non-profit research institutions to promote research in chemistry and the life sciences, broadly interpreted, and particularly to foster the invention of methods, instruments, and materials that will open up new avenues of research in science.
The purpose of the Beckman Scholars Program is to provide an in-depth, sustained undergraduate research experience in chemistry, biochemistry, biological, and medical sciences, or some interdisciplinary combination of these subjects, for exceptionally talented, full-time undergraduate students at accredited US four-year colleges and universities; young people who ultimately will become prominent leaders in their scientific and professional pursuits.
The Program's financial support for a student and mentor over 15 continuous months of research, in conjunction with the Annual Beckman Symposium, offers an academically stimulating and unique educational experience. The Program encourages the participation of both junior, as well as more senior academics to serve as Faculty Mentors.
JHU, as an institution, can apply if at least 12 faculty members become mentors. Interested applicants should submit the following documents to email@example.com:
Questions? Email the Research Development Team at firstname.lastname@example.org
No application deadline
The Michael J. Fox Foundation is sponsoring a $2 million prize to the first team to develop a viable selective alpha-synuclein PET tracer and agree to make that tracer available broadly.
The ability to image alpha-synuclein deposition
in the brain would be a game-changing achievement for the Parkinson's
disease (PD) field. The accumulation of aggregated alpha-synuclein is
a pathological hallmark of PD and a priority target for drug development
given its hypothesized contribution to neurodegeneration. In vivo imaging
of alpha-synuclein pathology could be useful as a biomarker of the presence
of disease and disease progression and as a pharmacodynamic tool for
drug development. With this prize, the Foundation seeks to attract research
teams and accelerate momentum to speed the development of such a tracer.
Contestants: Anyone is eligible for
the prize who agrees to all contest rules. Contestants may be MJFF funded
or not and can be from either academia or industry.
Criteria for winning: The winning contestant
must demonstrate that the radiotracer binds with relatively high selectivity
to alpha-synuclein according to pre-specified criteria and must demonstrate
proof-of-concept in human subjects, including people with Parkinson's
disease and/or another synucleinopathy. See below for more details on
Timeline: There is no deadline
for submissions. The $2 million award will be issued to the first
contestant who submits compelling evidence of a viable selective tracer
and agrees to its widespread use. If no award is given by mid-2018,
The Michael J. Fox Foundation will evaluate the state of the field and
utility of such a prize.